Reimagining the ECG with Artificial Intelligence
Reveal hidden risk and enable earlier clinical action with any electrocardiogram.
The electrocardiogram has always held far more information than medicine could interpret. ECG AI allows us to translate these signals into actionable diagnostic and prognostic insights which will greatly enhance clinical care.
John Jefferies, MD, FACC, FAHA, FHFSA
Former President, American Heart Association Mid-South Chapter
Built for Clinical and Consumer Scale
Deploy agentic medical AI with real-time insight, seamless integration, and operational reliability across care and consumer workflows.
Hidden Risk, Revealed Early.
Identify subclinical cardiovascular risk hidden in otherwise normal electrocardiograms to enable earlier and more precise intervention.
Risk identified
Clinically Validated at Scale.
Built on more than 10 million electrocardiograms and externally validated to meet the demands of real world clinical use.
Rewrite History.
Analyze retrospective and prospective electrocardiograms to identify patients at risk earlier and guide proactive care.
More Precise Clinical Decisions.
Support targeted ordering of echocardiograms, labs, and follow up procedures by surfacing risk where it matters most.
Built for Clinical and Consumer Scale.
Integrates seamlessly across medical devices, health systems, telehealth platforms, and consumer technologies to empower decisions everywhere.
Ready for Real World Deployment.
PHI secure and compliant, easy to integrate via RESTful APIs, with existing Category III codes, live deployments, and proven clinical workflows.
FDA
BREAKTHROUGH
DEVICE DESIGNATION
9+1AI Receives FDA Breakthrough Device Designation for ECG AI Diagnostics
9+1AI has been granted FDA Breakthrough Device Designation for its electrocardiogram based artificial intelligence technology, recognizing its potential to provide more effective diagnosis of serious cardiovascular conditions and to address unmet clinical needs through earlier risk identification.